ASH's fully open-access journal for haematology, including real-world outcomes, phase 1 and 2 trials and the ASH clinical practice guidelines.
Blood Advances (Blood Adv) is the fully open-access haematology journal of the American Society of Hematology (ASH), launched in 2016 as the open-access companion to Blood and published by the society itself, with CC BY licences available. It publishes real-world outcomes, phase 1 and 2 trials, registry analyses and translational studies in blood cancers, and it carries the ASH clinical practice guidelines, for example on venous thromboembolism in cancer. Its readers are haematologists and haematology-oncology trialists who want early-phase and real-world evidence without a paywall. Within OnCo it is linked from the Eunice Wang biography, and it is the place to look for ASH guidelines and early-phase blood cancer trials.
Physician who serves as Director of Christian Medical College, Vellore, the not-for-profit teaching hospital and medical school in Tamil Nadu, India.
Internal medicine oncologist who directs the Comprehensive Cancer Center Freiburg and heads its clinical trials unit.
Eunice Wang is an AML trialist who helped bring FLT3 and menin inhibitors to patients.
Physician who directs the Masonic Cancer Center at the University of Minnesota, the NCI-designated comprehensive cancer centre in Minneapolis.
Physician who directs the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine in Houston, an NCI-designated comprehensive cancer centre.
Shares American Society of Hematology, Blood.